In addition to this, it was not possible to identify other factors that may affect OS, beyond the HR status of the tumours, such as comorbidities, HER2 status, site of metastasis, metastatic tumour burden, and the use of prior therapy for breast cancer, as these variables are not available in the Cancer Register. This evidence concerns the gene ERBB2 and neoplasm.